Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan

請用此 Handle URI 來引用此文件： http://ir.sinica.edu.tw/handle/201000000A/83304

題名:	Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan
作者:	Hsieh, SM Liu, MC Chen, YH Lee, WS Hwang, SJ Cheng, SH Ko, WC Hwang, KP Wang, NC Lee, YL Lin, YL Shih, SR Huang, CG Liao, CC Liang, JJ Chang, CS Chen, C Lien, CE Tai, IC Lin, TY
公開日期:	2021-12
關聯:	The Lancet. Respiratory medicine 9(12), 1396-1406
URI:	http://ir.sinica.edu.tw/handle/201000000A/83304
URL:	http://dx.doi.org/10.1016/S2213-2600(21)00402-1
顯示於：	生物醫學科學研究所

顯示文件完整紀錄

checked on 2025/5/9

檢查